Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Cladribine Tablets: In Relapsing-Remitting Multiple Sclerosis.

CNS drugs·2020
Same author

Asenapine: A Review in Schizophrenia.

CNS drugs·2016
Same author

AFREZZA® (insulin human) Inhalation Powder: A Review in Diabetes Mellitus.

Drugs·2015
Same author

13-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults.

Drugs·2015
Same author

Acamprosate: A Review of Its Use in Alcohol Dependence.

Drugs·2015
Same author

Diclofenac sodium injection (akis(®), dicloin (®)): a review of its use in the management of pain.

Clinical drug investigation·2015

Related Experiment Videos

Cladribine tablets: in relapsing-remitting multiple sclerosis.

Victoria J Muir1, Greg L Plosker

  • 1Adis, a Wolters Kluwer Business, Auckland, New Zealand. demail@adis.co.nz

CNS Drugs
|February 18, 2011
PubMed
Summary
This summary is machine-generated.

Oral cladribine significantly reduced relapse rates and disability progression in relapsing-remitting multiple sclerosis patients. This oral therapy also decreased brain lesions, offering a new treatment option.

Related Experiment Videos

Area of Science:

  • Neuroimmunology
  • Pharmacology

Background:

  • Relapsing-remitting multiple sclerosis (RRMS) is a chronic autoimmune disease.
  • Current treatments for RRMS often involve frequent administration or injections.
  • Oral cladribine offers a potential convenient therapeutic option for RRMS.

Purpose of the Study:

  • To evaluate the efficacy and safety of oral cladribine in patients with RRMS.
  • To assess the impact of oral cladribine on relapse rates, disability progression, and MRI-assessed brain lesions.

Main Methods:

  • The CLARITY trial was a large, well-designed Phase III clinical study.
  • Patients with RRMS received short-course oral cladribine (3.5 or 5.25 mg/kg cumulative dose) or placebo.
  • Outcomes were assessed over 96 weeks, including annualized relapse rates, disability progression, and MRI lesion counts.

Main Results:

  • Oral cladribine significantly reduced annualized relapse rates compared to placebo.
  • A higher proportion of patients on cladribine were relapse-free at 96 weeks.
  • Significant reductions in disability progression risk and brain lesions were observed with cladribine.
  • Treatment benefits were consistent across various baseline patient characteristics.
  • Increased incidence of lymphocytopenia, herpes zoster, and neoplasms were noted with cladribine.

Conclusions:

  • Short-course oral cladribine is an effective treatment for reducing disease activity in RRMS.
  • Oral cladribine demonstrates significant efficacy in reducing relapses, disability progression, and MRI lesions.
  • The safety profile includes increased risks of lymphocytopenia and infections, requiring careful monitoring.